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osting by EAbstract Normal adult inbred SWR/J mice were used to investigate the teratogenic and other pos-
sible toxic effects of various dose levels of sildenaﬁl citrate (Viagra) on fetuses. Multiple dose levels
of 6.5, 13.0, 19.5, 26.0, 32.5 or 40.0 mg of sildenaﬁl citrate/kg body weight (which correspond to the
multiples of 1, 2, 3, 4, 5 or 6 of human 50 mg Viagra, respectively) were orally administered into
pregnant mice on days 7–9, 10–12 or 13–15 of gestation. On day 17 of pregnancy, all fetuses were
removed and examined for toxic phenomena (embryo-fetal toxicity) and for external, internal and
skeletal malformations. A total of 285 pregnant mice were used in the present study.
None of the dams treated with sildenaﬁl citrate at any of the oral dose levels used in the present
study died during the experimental period and all dams treated with the drug failed to reveal overt
signs of maternal toxicity. Moreover, the results of the present study clearly demonstrate that none
of the multiple oral dose levels of the drug at any time interval used has induced any external, inter-
nal or skeletal malformations in the fetuses obtained from treated females.
However, the dose level of 40 mg/kg body weight of sildenaﬁl citrate has a growth suppressing
effect on alive fetuses when it was administered at all the time intervals used in the present study.4675762; fax: +966 14678514.
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136 F.M. Abou-Tarboush et al.Furthermore, the dose levels 26.0, 32.5 and 40 mg/kg of the drug have embryo-fetal toxicity when
the drug is applied on days 13–15 of gestation. The possible mechanisms involved in the embryo-
fetal toxicity and fetal growth suppressing effects of sildenaﬁl citrate were discussed.
The results of this study have important implications for the widespread use of this drug.
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Sildenaﬁl citrate (Viagra) is an oral medication used to treat
male erectile dysfunction by the inhibition of phosphodiester-
ase-5 in the corpus cavernosum and subsequent facilitation
of penile erection (Vatansever et al., 2003). Since its introduc-
tion in 1998, sildenaﬁl citrate has been used to treat over 27
million men with this problem worldwide (Boyce and Umland,
2001; Glenn et al., 2009). Moreover, the drug is used increas-
ingly by men of reproductive age and there is now robust evi-
dence that its use in recreation has gained credence in young
healthy males as a sexual enhancer as well in older men requir-
ing it for impotence problems (Aldridge and Measham, 1999;
Smith and Romanelli, 2005). Furthermore, its use is also rap-
idly increasing in the population of young men who suffer
from impotence related to medical conditions, such as diabetes
and spinal cord injuries (Monga et al., 1999).
Sildenaﬁl citrate has been used successfully in males to
remediate problems associated with impaired neural and/or
hemodynamic response to sexual stimulation (Krenzelok,
2000). In addition, it is effective in the treatment of pulmonary
hypertension in hemoglobinopathies (Derchi and Forni, 2005).
Moreover, sildenaﬁl citrate could be an alternative in the treat-
ment of intrauterine growth retardation (IUGR) and prema-
ture delivery (Villanueva-Garcia et al., 2007).
The widespread use of sildenaﬁl citrate is of concern, be-
cause it is a selective type 5 phosphadiesterase (PDE) inhibitor,
and PDE inhibitors have been shown to affect sperm function
and embryo development (Tournaye et al., 1993; Scott and
Smith, 1995; Glenn et al., 2007, 2009). Although a few studies
(Abbott et al., 2004; Product Monograph, 2006; Villanueva-
Garcia et al., 2007) have conducted to investigate sildenaﬁl cit-
rate’s teratogenic effect in experimental animals, all of those
studies indicated that it is not a teratogenic agent. However,
other studies (Refuerzo et al., 2006; Glenn et al., 2009) indi-
cated that sildenaﬁl citrate could affect fetal size and early em-
bryo development, respectively. Therefore, the aim of the
present study was to investigate the teratogenic, toxic and
growth suppressing effects of various dose levels of sildenaﬁl
citrate on the embryos and fetuses of SWR/J mice when
administered into pregnant females during different days of
gestation.
2. Materials and methods
Inbred normal SWR/J male and female mice, 8–10 weeks old
and weighing 25–30 g were used in the present study. Animals
were kept and bred under controlled room temperature of
22 ± 1 C, a relative humidity of 45 ± 5% and a light/dark
cycle of 10/14 h. Rodent chow (commercially available in
Saudi Arabia) and water were offered ad libitum.
In each box, 3–4 nulliparous females were caged together
with a single male. The day the vaginal plug was detected
was considered as day 0 (D0) of gestation and the pregnant fe-males were placed in separate cages. A total of 285 pregnant
females were used, and were divided into four groups (I–IV),
15 females each. The females of each of the three groups were
orally treated on days 7–9, 10–12 or 13–15 of pregnancy with
multiple dose levels of 6.5, 13.0, 19.5, 26.0, 32.5 or 40.0 mg/
kg body weight of sildenaﬁl citrate (Pﬁzer Inc., USA) dissolved
in sterile normal saline. The fourth group of pregnant females
served as a control group and received 0.4 ml of the vehicle
alone (sterile normal saline).
On day 17 (D17) of gestation, pregnant females from all
groups were killed by cervical dislocation, the abdominal wall
of each female was opened and both uterine horns were
promptly exposed to their full extent. The number of resorbed
and intact fetuses was counted and recoded. The uterine horns
were then opened to determine the number of alive and dead
fetuses. Spontaneous movement, reddish color, size and/or
movement induced with a forceps on the neck or the head of
the fetus were the criteria used to distinguish between alive
and dead fetuses. The relative positions of fetuses and resorp-
tion of dead ones were also recorded. Alive fetuses were care-
fully examined under a stereoscopic microscope for gross
malformations and were accordingly classiﬁed as normal or
abnormal. Normal and abnormal alive fetuses were removed
onto paper towels, dried up and weighed. Twenty fetuses/treat-
ment dose levels were cleared and stained according to the
method of McLeod (1980) for the study of skeletal abnormal-
ities. Twenty fetuses/control groups were similarly prepared
for skeletal malformation examination.
2.1. Statistical analysis
The data obtained were statistically analyzed using a 2 · 2 con-
tingency table (v2) for the actual number of resorptions ob-
served, and the signiﬁcance of the difference between means
of sildenaﬁl citrate-treated and control group was calculated
by Student’s t-test (Sokal and Rohlf, 1981).
3. Results
None of the dams treated with sildenaﬁl citrate at any of the
dose levels used in the present study died during the experi-
mental period and all the dams treated with the drug failed
to reveal overt signs of maternal toxicity.
Data in Table 1 show a signiﬁcant (p< 0.05) increase in the
percentage of resorption and a simultaneous reduction in the
mean alive fetal body weight at the dose level of 40 mg/kg bo-
dy weight when the drug was applied on days 7–9 of gestation.
Data in Table 2 show a signiﬁcant (p< 0.05) reduction in
the mean alive fetal body weight at the dose level of 40 mg/
kg body weight when the drug was administered on days 10–
12 of pregnancy.
Data in Table 3 show a signiﬁcant (p< 0.05) increase in the
percentages of resorptions at the dose levels of 26.0, 32.5 and
40.0 mg/kg body weight when the drug was applied on days
Table 1 Effect of the administration of various doses of sildenaﬁl citrate (Viagra) applied to SWR/J female mice on days 7–9 of
pregnancy on the fetuses.
Dose used
(mg/g)
No. of
dams used
No. of
implantation sites
No. of
fetuses/dam
(Mean ± SE)
No. of alive
fetuses/dam (Mean ± SE)
No. of resorptions
(1%)
Alive fetal
body wt. in
g (Mean ± SE)
Abnormalities observed
Control 15 164 10.93 ± 0.42 10.60 ± 1.06 5 (3.05) 0.82 ± 0.017 None
6.5 15 168 11.20 ± 0.35 10.73 ± 0.85 7 (4.17) 0.83 ± 0.020 None
13.0 15 160 10.67 ± 0.11 10.20 ± 0.81 7 (4.32) 0.84 ± 0.018 None
19.5 15 169 11.27 ± 0.43 10.60 ± 0.80 10 (5.92) 0.86 ± 0.017 None
26 15 168 11.20 ± 0.80 10.33 ± 0.69 13 (7.74) 0.79 ± 0.022 None
32.5 15 166 11.07 ± 0.63 10.27 ± 0.71 12 (7.23) 0.78 ± 0.021 None
40.0 15 165 11.00 ± 0.78 10.07 ± 0.69 14 (8.48)* 0.63 ± 0.023* None
* Differences are statistically signiﬁcant from the control group at p< 0.05.
Table 2 Effect of the administration of various doses of sildenaﬁl citrate (Viagra) applied to SWR/J female mice on days 10–12 of
pregnancy on the fetuses.
Dose used
(mg/g)
No. of
dams used
No. of
implantation sites
No. of
fetuses/dam
(Mean ± SE)
No. of alive
fetuses/dam
(Mean ± SE)
No. of
resorptions (1%)
Alive fetal
body wt. in g
(Mean ± SE)
Abnormalities observed
Control 15 164 10.93 ± 0.42 10.60 ± 1.06 5 (3.05) 0.82 ± 0.017 None
6.5 15 167 11.13 ± 0.39 10.67 ± 0.85 7 (4.19) 0.83 ± 0.019 None
13.0 15 168 11.20 ± 0.86 10.53 ± 0.84 10 (5.95) 0.79 ± 0.030 None
19.5 15 166 11.07 ± 0.85 10.67 ± 0.77 6 (3.61) 0.79 ± 0.022 None
26.0 15 163 10.87 ± 0.85 10.33 ± 0.56 8 (4.91) 0.77 ± 0.023 None
32.5 15 161 10.73 ± 0.72 10.00 ± 0.81 11 (6.83) 0.78 ± 0.031 None
40.0 15 159 10.60 ± 0.53 9.80 ± 0.80 12 (7.55) 0.71 ± 0.028* None
* Differences are statistically signiﬁcant from the control group at p< 0.05.
Table 3 Effect of the administration of various doses of sildenaﬁl citrate (Viagra) applied to SWR/J female mice on days 13–15 of
pregnancy on the fetuses.
Dose used
(mg/g)
No. of
dams used
No. of
implantation sites
No. of
fetuses/dam
(Mean ± SE)
No. of alive
fetuses/dam
(Mean ± SE)
No. of
resorptions
(1%)
Alive fetal
body wt.
in g (Mean ± SE)
Abnormalities observed
Control 15 164 10.93 ± 0.42 10.60 ± 1.06 5 (3.05) 0.82 ± 0.017 None
6.5 15 167 11.13 ± 0.39 10.27 ± 0.83 13 (7.78) 0.85 ± 0.021 None
13.0 15 168 11.20 ± 0.86 10.60 ± 0.84 9 (5.36) 0.84 ± 0.022 None
19.5 15 169 11.27 ± 0.87 10.53 ± 0.61 11 (6.51) 0.78 ± 0.028 None
26 15 164 10.93 ± 0.85 10.00 ± 0.31 14 (8.54)* 0.80 ± 0.029 None
32.5 15 162 10.80 ± 0.49 9.93 ± 0.42 13 (8.02)* 0.77 ± 0.024 None
40.0 15 163 10.87 ± 0.75 9.93 ± 0.57 14 (8.59)* 0.69 ± 0.019* None
* Differences are statistically signiﬁcant from the control group at p< 0.05.
Developmental toxicity of orally administered sildenaﬁl citrate (Viagra) in SWR/J mice 13713–15 of gestation. Moreover, there is a signiﬁcant (p< 0.05)
reduction in the mean alive fetal body weight when the drug
was administrated on the same days.
However, none of the drug dose levels used has induced any
external, internal or skeletal malformations in any of the fe-
tuses obtained from sildenaﬁl citrate-treated females at any
day of gestation used in the present study.
4. Discussion
None of the dams treated with sildenaﬁl citrate at any of the
oral dose levels used in the present study died during theexperimental period and all dams treated with the drug failed
to reveal overt signs of maternal toxicity. Moreover, the re-
sults of the present study clearly demonstrate that the multi-
ple oral dose levels of sildenaﬁl citrate ranging from 6.5 to
40.0 mg/kg body weight into SWR/J pregnant mice on days
7–9, 10–12 or 13–15 of gestation did not induce any external,
internal or skeletal malformations in the fetuses obtained
from such treated females. Therefore, these results are in
agreement with what is known about this drug from the
few studies that have been documented (Abbott et al.,
2004; Product Monograph, 2006; Villanueva-Garcia et al.,
2007).
138 F.M. Abou-Tarboush et al.However, the dose level 40 mg/kg body weight of sildenaﬁl
citrate has growth suppressing effect on fetuses obtained from
pregnant females when it was administrated on all days in the
present study. Furthermore, the dose levels 26.0, 32.5 and
40 mg/kg of the drug have embryo-fetotoxicity when it was ap-
plied on days 13–15 of pregnancy. Such results are also consis-
tent with the results of Refuerzo et al. (2006) and Glenn et al.
(2009) who found that sildenaﬁl citrate resulted in a decrease in
fetal size, fertilization rates and embryo development in animal
models (rats and mice).
Alternations in intracellular Ca2+ distribution may be the
key to the effects of sildenaﬁl citrate observed in the present
study. There is strong evidence that free intracellular Ca2+
controls cell division in embryos (Webb and Miller, 2003).
Moreover, Blancato and Seyler (1990) concluded that both
Ca2+ ﬂux and distribution to particular sites are required
for normal embryo development. In addition, calcium deple-
tion by PDE inhibitors has been reported by Ghalayini
(2004), and the calcium channels facilitating both ﬂux and
distribution are tightly regulated by cAMP-dependent phos-
phorylation and minor changes in concentrations of either
cAMP or cGMP have major impact on embryonic cell prolif-
eration (Fischmeister and Hartzell, 1991; Grealy and Sreenan,
1999).
Another cause of the toxic and growth suppressing effects
of sildenaﬁl citrate on embryo development may be due to
PDE inhibitor effects on the embryos’ DNA synthesis and re-
pair (Glenn et al., 2009). Souness et al. (1992) showed that
inhibitors of PDE types 3 and 4 impair DNA synthesis and
proliferation in pig aortic smooth muscle may be via the eleva-
tion of intracellular cAMP. Pentoxifylline (a PDE type 4 inhib-
itor) has also been shown to inhibit DNA repair in vitro during
the S and G2 phases in a human ovarian cell line (Schiano
et al., 1991).
Apoptosis is a further mechanism by which PDE inhibi-
tors may suppress the growth of the embryos and/or destroy
them (Glenn et al., 2009). The mechanism by which this oc-
curs has been studied in eosinophils and pulmonary endo-
thelial cells and is related to a sustained increase in
intracellular cGMP concentration (Wang et al., 2005; Zhu
et al., 2005).
Finally, sildenaﬁl citrate can enhance nitric oxide (NO) pro-
duction in embryos and such action could cause damage to
such embryos and reduce their survival if NO is generated in
excess (Moncada and Higgs, 1991; Barroso et al., 1998; Glenn
et al., 2009). However, further studies are needed to elucidate
the mechanism(s) by which the impairment occurs.
In conclusion, the present study demonstrates that sildenaﬁl
citrate (Viagra) has embryo-fetotoxicity and growth suppress-
ing effects when applied during development in an animal
model. This has important implications for the widespread
use of this drug. However, there is still limited information
about the efﬁcacy of sildenaﬁl citrate for the treatment of
IUGR and premature delivery.Acknowledgement
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